{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"description":"the number of subjects with a confirmed overall Complete response (CR) or Partial response (PR) by investigator assessment using the Response evaluation criteria in solid tumors (RECIST 1.1 criteria). To determine the overall response, all target and non-target lesions will be assessed using modified RECIST 1.1 criteria.","groups":[{"description":"Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.","id":"OG000","title":"Cohort A"},{"description":"Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity","id":"OG001","title":"Cohort B"},{"description":"Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity","id":"OG002","title":"Cohort C"},{"description":"Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity","id":"OG003","title":"Cohort D"}],"paramType":"NUMBER","populationDescription":"All Treated population - All subjects who receive at least one dose of study medication are comprised the All Treated subjects (ATS) population","reportingStatus":"POSTED","timeFrame":"Approximately 2 years","title":"Overall Response (OR) for Each Cohort","type":"SECONDARY","unitOfMeasure":"Number of participants"}